Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration.
AnneMarthe MjelstadGustav ZakariassonAntonios ValachisPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2019)
Our hypothesis-generating results support a more individualized approach on antiresorptive treatment including the lack of detrimental effect when the treatment is delayed, the potential benefit of switching strategy after skeletal disease progression or SSE, and the benefit of continuing antiresorptive treatment beyond 2 years.
Keyphrases